Last $4.75 USD
Change Today -0.02 / -0.42%
Volume 1.4K
BONE On Other Exchanges
As of 10:39 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

bacterin international holdi (BONE) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/14 - $14.10
52 Week Low
12/18/13 - $3.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

bacterin international holdi (BONE) Related Businessweek News

No Related Businessweek News Found

bacterin international holdi (BONE) Details

Bacterin International Holdings, Inc. develops, manufactures, and markets biologics products in the United States and internationally. The company’s Biologics Division offers products that are used in various applications, including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing, neurosurgery, and subchondral bone repair. Its biologics products include OsteoSponge, which provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC, a subchondral bone void filler; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as is used in conjunction with a hardware plate system. This segment also provides OsteoLock and BacFast facet stabilization dowels that are used to augment spinal procedures; and hMatrix dermal scaffold, which promotes cellular ingrowth, tissue vascularization, and regeneration. In addition, Biologics Division manufactures and sells sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled allografts; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Bacterin International Holdings, Inc.’s Medical Devices division offers coatings for medical devices; OsteoSelect DBM putty, an osteoinductive and osteoconductive product used by surgeons as a bone void filler in the extremities and pelvis; and custom surgical instruments for use with allografts. This segment also sells Via and Elutia, surgical drain series products used to drain exudate from a surgical site. The company markets its products through direct sales, as well as through distributor relationships. Bacterin International Holdings, Inc. is headquartered in Belgrade, Montana.

128 Employees
Last Reported Date: 03/27/14
Founded in 2010

bacterin international holdi (BONE) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $143.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $422.3K
Chief Operating Officer
Total Annual Compensation: $338.6K
Chief Scientific Officer
Total Annual Compensation: $271.1K
Compensation as of Fiscal Year 2013.

bacterin international holdi (BONE) Key Developments

Bacterin International Holdings, Inc. Appoints David Goodman as New Board Member

Bacterin International Holdings, Inc. announced the addition of David Goodman, MD, MSE to the board of directors. Dr. Goodman brings extensive experience in executive management through previous roles as CEO of SEDLine and EVP of Business Development for Masimo. The Board unanimously elected Dr. Goodman to fill the vacancy created by Mitchell Godfrey's recent resignation. Dr. Goodman currently serves as Co-Founder and CMO of FirstVitals Health & Wellness, a technology-enabled service company focused on preventing complications such as foot ulcers and lower extremity amputations in people with diabetes. He also serves on the board of NEUROMetrix and was previously on the board of Sound Surgical prior to its acquisition by Solta Medical.

Bacterin International Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Bacterin International Holdings, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenue was $8,883,932 against $8,266,848 a year ago. Loss from operations was $1,332,009 against $1,866,984 a year ago. Net loss was $1,900,430 or $0.35 basic and dilutive per share against $2,483,091 or $0.55 basic and dilutive per share a year ago. EBITDA was $769,645 against $1,427,054 a year ago. For the six months, the company's total revenue was $17,796,902 against $16,885,655 a year ago. Loss from operations was $2,524,010 against $3,100,403 a year ago. Net loss was $6,040,685 or $1.11 basic and dilutive per share against $4,152,349 or $0.94 basic and dilutive per share a year ago. EBITDA was $1,484,829 against $2,491,767 a year ago.

Bacterin International Mulls Acquisitions; Files For Offering

Bacterin International Holdings, Inc. (AMEX:BONE) has filed a follow-on equity offering and make seek acquisitions. The company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes. General corporate purposes may include providing working capital, funding capital expenditures, or paying for acquisitions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BONE:US $4.75 USD -0.02

BONE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biolase Inc $2.14 USD -0.03
Cytori Therapeutics Inc $1.37 USD 0.00
Stereotaxis Inc $2.99 USD -0.0074
Uroplasty Inc $2.65 USD +0.02
Vision Sciences Inc/DE $0.92 USD +0.0241
View Industry Companies

Industry Analysis


Industry Average

Valuation BONE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BACTERIN INTERNATIONAL HOLDI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at